Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

The lawsuit claims Natera aggressively recruited bioinformatics scientists from Guardant to “jumpstart its lagging position ...

In a report released today, William Bonello from Craig-Hallum maintained a Buy rating on Natera (NTRA – Research Report). The company’s shares ...

Guardant Health is overcoming skepticism with new cancer tests. Learn why GH stock is a buy, with strong growth and a shift toward multi-cancer detection.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rhythm Pharmaceuticals (RYTM – Research Report), ...

Guardant Health (NASDAQ:GH – Get Free Report) had its target price upped by Piper Sandler from $34.00 to $50.00 in a report ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

Guggenheim restated their buy rating on shares of Guardant Health (NASDAQ:GH – Free Report) in a report released on Monday ...

Guardant Health is a leader in liquid biopsy ... and Guardant commands the second-largest market share after the market leader Natera. Reveal’s differentiating feature is that it is "tumor ...

TD Cowen analyst Dan Brennan raised the firm’s price target on Guardant Health (GH) to $56 from $42 and keeps a Buy rating on the shares. The firm said results were inline with the ...

Guardant Health specializes in precision oncology, developing advanced blood tests for cancer detection and management. The core of its business lies in liquid biopsies for both advanced-stage and ...